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The PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumour suppressor is mutated in 40–50% of human
endometrial cancers. PTEN exerts its effects in part via inhibition of the antiapoptotic protein AKT. We demonstrate that two
endometrial cancer cell lines that harbour PTEN mutations, Ishikawa and RL95-2, have high levels of phosphorylated AKT and high
AKT kinase activity. Two additional endometrial cancer cell lines that express wild-type PTEN, Hec1A and KLE, have little
phosphorylated AKT and minimal demonstrable AKT kinase activity. We tested a potential inhibitor of the AKT pathway, API-59CJ-
OMe, in these four cell lines. We found that API-59CJ-OMe inhibits AKT kinase activity and induces apoptosis in the Ishikawa and
RL95-2 cell lines with high AKT activity, but has little effect on Hec1A and KLE cells without AKT activity. API-59CJ-OMe may
therefore have therapeutic potential for those endometrial cancers that harbour PTEN mutations and AKT activation.
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Endometrial cancer is the most common gynaecologic malignancy
in developed countries, with approximately 40000 new diagnoses
each year in the US alone. Mutations of the tumour suppressor
PTEN are found in 40–50% of human endometrial cancers
(Tashiro et al, 1997; Ali, 2000). PTEN is also frequently mutated
in brain, breast, and prostate cancers (Cairns et al, 1997; Li and
Sun, 1998; Davies et al, 1999). PTEN is thought to function as a
tumour suppressor due to its ability to block G1 cell cycle
progression, induce apoptosis, and negatively regulate the PI3-K/
AKT cell survival pathway (Stambolic et al, 1998). Accordingly, in
cancer cells with PTEN mutation or deletion, AKT activity is
dramatically elevated (Kanamori et al, 2001). AKT is a serine/
threonine kinase that is activated in response to growth factors or
cytokines by a mechanism involving phosphoinositide 3-kinase
(PI3-K) and phosphoinositide-dependent kinase-1 (PDK-1)
(Franke et al, 1997; Kulik et al, 1997). AKT has three isoforms:
AKT1 (PKBa), AKT2 (PKBb), and AKT3 (PKBg) (Datta et al, 1999).
These isoforms have greater than 85% sequence identity and have
the same structural organisation. Amplification of the AKT2
oncogene and high AKT kinase activity have been detected in
breast, pancreatic, ovarian, brain, prostate, and gastric cancers
(Cheng et al, 1992; Bellacosa et al, 1995).
AKT provides a survival signal that protects cells from apoptosis
induced by various stresses (Franke et al, 1997; Kulik et al, 1997).
Some examples of the known mechanisms by which AKT prevents
apoptosis are the phosphorylation of Bad, glycogen synthase
kinase-3 (GSK-3), forkhead transcription factor (FKHR), and
caspase-9 (Del Peso et al, 1997; Cardone et al, 1998; Pap and
Cooper, 1998; Brunet et al, 1999). Phosphorylation of these
proteins results in inactivation of their apoptotic functions. AKT
may suppress apoptosis by stimulating the transactivation
potential of the RelA/p65 subunit of NF-kappaB (Romashkova
and Makarov, 1999; Madrid et al, 2000). AKT may also enhance the
ubiquitination-promoting function of Mdm2, resulting in ubiqui-
tin-mediated degradation of the tumour suppressor p53 (Ogawara
et al, 2002).
Development of potent AKT inhibitors is a promising ther-
apeutic strategy for endometrial carcinoma. We have employed a
bioinformatics approach to identify potential inhibitors of the AKT
pathway (Wang and Yang, manuscript in preparation). We first
performed a Western blot analysis to probe the level of
phosphorylated AKT (p-AKT) in the National Cancer Institute
(NCI) 60 human cancer cell lines. Correlation analysis was
performed of the in vitro anticancer activity of 35000 compounds
in the NCI’s anticancer database, and the p-AKT levels in the NCI
60 human cancer cell lines to identify compounds whose in vitro
anticancer activities significantly correlated with the p-AKT level
in the 60 cancer cell lines. Compounds whose in vitro anticancer
activities significantly correlated with the p-AKT level in the 60
cancer cell lines were considered as candidate inhibitors for the
AKT pathway. API-59CJ-OMe (9-methoxy-2-methylellipticinium
acetate) was identified as a potential inhibitor. Our further
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yevaluations in human prostate and breast cancer cell lines showed
that API-59CJ-OMe potently inhibits cell growth and induces
apoptosis in cell lines with high levels of p-AKT, but has minimal
activity in cell lines with low levels of p-AKT (Wang and Yang,
manuscript in preparation), suggesting that API-59CJ-OMe may
target the AKT pathway.
In the present study, we tested API-59CJ-OMe in PTEN-defective
endometrial cancer cells. We found that API-59CJ-OMe selectively
inhibits AKT kinase activity and induces apoptosis in endometrial
cancer cell lines expressing high levels of AKT activity. API-59CJ-
OMe has little effect in endometrial cancer cells lacking AKT
activity. This is the first report of a potential AKT inhibitor in
endometrial cancer.
MATERIALS AND METHODS
Cell lines
Hec1A, RL95-2, and KLE human endometrial cancer cell lines were
purchased from American Type Culture Collection (Manassas, VA,
USA). Ishikawa human endometrial cancer cell line has been
previously described and was obtained from Dr Masato Nishida
(Holinka et al, 1986). Cells were maintained in 90% Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum and antibiotics (5000Uml
1 penicillin G, 5000mgml
1
streptomycin) (Gibco/BRL Life Technologies, Inc., Rockville, MD,
USA) at 371Ci n5 %C O 2.
Western blot analysis
To analyse levels of phosphorylation of AKT, PDK1, and ERK1/2
proteins, cells were plated at 1.210
6cells. 100mm
1 dish 1 day
prior to treatment. Cells were then treated with API-59CJ-OMe at
the indicated dose for 48 or 72h before harvesting. In total, 100mg
of total protein from cell lysates was separated on 10% SDS–
polyacrylamide gels and blotted with a 1:1000 dilution of
antibodies against phospho-AKT (Ser 473 or Thr 308), phospho-
PDK1 (Ser 241), phospho-ERK1/2 (Thr202/Tyr204), phospho-JNK
(Thr 183/Tyr 185), phospho-SGK (Ser 78), phospho-PKCz/l (Thr
410/403), phospho-PKCa/b (Thr 638/641), total AKT, or total
PTEN (Cell Signaling Tech., Beverly, MA, USA). The same
membranes were analysed with a 1:2500 dilution of anti-GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) monoclonal anti-
body (Chemicon International, Inc., Temecula, CA, USA) as a
protein loading control. All blots were incubated with 1:10000
dilution of secondary alkaline phosphatase-conjugated anti-mouse
or anti-rabbit antibody (Amersham Pharmacia Biotech., Piscat-
away, NJ, USA). Blots were scanned with ImageQuant Software
using an ECF Western blotting detection system (Amersham
Pharmacia Biotech., Piscataway, NJ, USA) on a Molecular
Dynamics STORM PhosphorImager (Sunnyvale, CA, USA). Each
Western blot was performed a minimum of three times.
AKT and ERK kinase assays
RL95-2 and Ishikawa cells were seeded at 1.210
6. cells in 100-
mm dishes for 24h before treatment. Cells were then exposed to
API-59CJ-OMe at 12 or 24mM for 48–72h. Protein (500mg) from
cell lysates was immunoprecipitated with either anti-AKT mono-
clonal antibody or anti-ERK monoclonal antibody. AKT kinase
assays and extracellular signal-regulated kinases (ERK) kinase
assays were performed using AKT and ERK kinase assay kits (Cell
Signaling Tech., Beverly, MA, USA) with glycogen synthase kinase-
3 (GSK-3) as a substrate for AKT and Elk-1 as a substrate for ERK.
Phospho-specific antibodies to GSK-3 a/b (Ser 21/9) and Elk-1 (Ser
383) were used for phosphorylated protein detection. At least three
independent repetitions were performed for each assay type. An
additional assay was performed to verify equal immunoprecipita-
tion of AKT from treated and untreated cells; AKT was
immunoprecipitated from cell lysates using the same anti-AKT
monoclonal antibody as described above. Cell lysates were
incubated and washed as per the kinase assay protocol, but then
separated via Western blot prior to the performance of the kinase
assay.
Apoptotic assay
API-59CJ-OMe was synthesised in Dr Shaomeng Wang’s labora-
tory at the University of Michigan. To quantitate the induction of
apoptosis by API-59CJ-OMe, cells from all four cell lines were
plated at 310
5 cells per 6-cm dish 1 day prior to exposure to
API-59CJ-OMe at 1.5, 6, 12, or 24mM. After 72h of treatment, cells
were harvested and fixed with 70% ethanol. Cells were then stained
with propidium iodide and analysed for reduction of DNA content
(sub-G1 profile) on a FACScan flow cytometer (Becton Dickinson,
San Jose, CA, USA). The results given are average values and
standard deviations from at least three separate experiments.
RESULTS
Expression of PTEN protein and phosphorylated AKT in
endometrial cancer cell lines
We first examined the expression of PTEN and phosphorylation of
AKT in the four human endometrial cancer cell lines, RL95-2,
Ishikawa, Hec1A, and KLE. Two of these cell lines, Hec1A and
KLE, express a considerable amount of PTEN protein, whereas the
other two, Ishikawa and RL95-2, express little or no PTEN protein
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Figure 1 Expression of PTEN and phospho-AKT in endometrial cancer
cell lines. Cell lysates were immunoblotted with phosphorylated AKT (Ser
473 or Thr 308), phosphorylated SGK (Ser 78), total AKT, or PTEN
antibody. The same lysates were immunoprecipitated with anti-AKT
antibody; AKT kinase assay was performed with GSK-3 as a substrate and
phospho-specific GSK-3 a/b (Ser 21/9) for phosphorylated protein
detection.
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and RL95-2 cell lines contain PTEN mutations, while Hec1A and
KLE cells express wild-type PTEN (Yaginuma et al, 2000). We also
found that Ishikawa and RL95-2 cell lines express high levels of
phosphorylated AKT and have high AKT kinase activity, whereas
Hec1A and KLE cells express little phosphorylated AKT and have
undetectable AKT kinase activity (Figure 1). However, phosphor-
ylation of serum- and glucocorticoid-inducible kinase (SGK), an
AKT-related serine/threonine kinase, is independent of PTEN
status in these cancer cell lines (Figure 1). Therefore, in these four
cell lines, there is perfect correlation between loss of PTEN
expression and overactivation of AKT kinase.
Inhibition of AKT kinase activity in human endometrial
cancer cell lines
Through a bioinformatics approach, we have identified a
nonpeptide small molecule inhibitor, API-59CJ-OMe, as a potential
inhibitor of the AKT pathway (Wang and Yang, manuscript in
preparation). The chemical structure of API-59CJ-OMe is shown in
Figure 2. We tested whether API-59CJ-OMe can inhibit AKT kinase
activity in RL95-2 and Ishikawa cells, the two cell lines with high
levels of AKT phosphorylation and kinase activity. Addition of
API-59CJ-OMe significantly inhibited AKT kinase activity when
GSK-3 is used as a substrate in RL95-2 and Ishikawa cells
(Figure 3). The amount of total AKT immunoprecipitated from cell
lysates was not affected by treatment with API-59CJ-OMe. API-
59CJ-OMe had no effect on ERK kinase activity. To further
demonstrate the selectivity of API-59CJ-OMe, we probed the same
cell lysates with antibodies against phosphorylated MAP kinases
(ERK1/2 and JNK1/2), phosphorylated AKT, phosphorylated SGK,
phosphorylated PKC isoforms, or phosphorylated PDK-1. As
shown in Figure 3, API-59CJ-OMe did not inhibit phosphorylation
of these proteins. Equal protein loading was demonstrated by
blotting the same membranes with GAPDH antibody. API-59CJ-
OMe did not affect kinases either upstream of AKT (PDK-1) or in a
distinct signal transduction pathway (ERK1/2 and JNK1/2) in
endometrial cancer cells. Of note, API-59CJ-OMe did not inhibit
phosphorylation of AKT itself at either Serine 473 or Threonine
308. This suggests that API-59CJ-OMe may act at the AKT kinase
level and is less likely to act upstream at kinases responsible for
either Serine 473 or Threonine 308 phosphorylation.
Induction of apoptosis in human endometrial cancer cell
lines with elevated AKT activity
We examined whether API-59CJ-OMe could induce apoptosis in
RL95-2 and Ishikawa endometrial cancer cell lines. We predicted
that inhibition of the AKT survival pathway by API-59CJ-OMe
would lead to apoptosis of these cancer cells. As expected,
exposure of API-59CJ-OMe at 12 and 24mM significantly induced
apoptosis in both RL95-2 and Ishikawa endometrial cancer cell
lines, which express high levels of phosphorylated AKT and AKT
kinase activity. API-59CJ-OMe had only minimal effects on Hec1A
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Figure 3 Effect of API-59CJ-OMe on AKT kinase activity and phosphorylation of other kinases. (A) After treatment with API-59CJ-OMe, cells were
harvested and cell lysates separated by 10% SDS–PAGE. Gels were analysed with phospho-specific antibodies to PDK1 (Ser 241), AKT (Ser 473 or Thr
308), ERK1/2 (Thr 202/Tyr 204), JNK (Thr 183/ Tyr 185), SGK (Ser 78), PKCz/l (Thr 410/403), and PKCa/b (Thr 638/641). The same lysates were
immunoprecipitated with anti-AKT or anti-ERK antibody, and kinase assays performed with GSK-3 as a substrate for AKT and Elk-1 as a substrate for ERK.
AKT (IP) represents the immunoprecipitation control: lysates were immunoprecipitated with mouse monoclonal anti-AKT antibody, separated by SDS–
PAGE, and stained with rabbit polyclonal anti-AKT antibody. Phospho-specific antibodies to GSK-3 a/b (Ser 21/9) and Elk-1 (Ser 383) were used for
phosphorylated protein detection.
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Figure 2 Chemical structure of API-59CJ-OMe, 9-methoxy-2-methy-
lellipticinium acetate.
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kinase activity (Figure 4). Lower doses (1.5 and 6mM), when
screened using MTT cell viability assays, had minimal effects on
cell number, and were significantly less effective at inducing
apoptosis in flow cytometry assays (data not shown).
DISCUSSION
PTEN mutation is a frequent event in human endometrial cancer.
Good correlation exists between loss of PTEN expression and high
levels of phosphorylated AKT in endometrial cancer cells
(Kanamori et al, 2001). High AKT kinase activity in cancer cells
may provide survival or proliferation signals and promote
oncogenesis (Franke et al, 1997; Kulik et al, 1997). Thus, inhibition
of AKT represents an attractive therapy for the treatment of
endometrial cancer. Inhibitors that target upstream regulators of
AKT such as PI3-K and PDK-1, or potentially target the pleckstrin
homology (PH) domain of AKT, have been reported (Hu et al,
2000; Ballif et al, 2001; Kozikowski et al, 2003; Meuillet et al, 2003).
Introduction of wild-type PTEN into endometrial cancer cells
harbouring PTEN mutation can inhibit cell growth (Lilja et al,
2001). In this report, we describe a potential small molecule
inhibitor of the AKT pathway. Small molecule drugs have several
advantages, including good delivery properties, good in vivo
stability, low probability of immune response, and low cost.
API-59CJ-OMe (or MMEA) belongs to the class of compounds
referred to as ellipticines. Ellipticines with a wide variety of
substitutions at the 2 and 9 positions have been evaluated as
potential antitumour agents, and there is evidence for several
different mechanisms of action for this group of drugs. The
ellipticines can bind directly to DNA, and the 2, 9 substituted
ellipticines may act as DNA ‘threaders’, intercalating into the DNA
strands (Harding and Grummitt, 2003). These compounds also
stabilise topoisomerase II–DNA complexes, and promote DNA
strand breakage. Some studies have also suggested that the
ellipticines may act to restore wild-type p53 function in cells with
mutant p53, although the results in our lab do not confirm this.
Finally, some of the ellipticines (9-hydroxyellipticines) may
promote generation of superoxide radicals, leading to DNA strand
breakage. Exactly how these described mechanisms relate to the
AKT inhibition we see in our system is still unclear, and we are
working further to clarify this. Several compounds have been used
in Phase I and II human trials for a variety of malignancies. The
compound appears to be metabolised by cytochrome P450, and
reported toxicities have varied widely across trials, which
have mostly involved 9-hydroxy compounds. There is in vitro
data that suggests that API-59CJ-OMe/MMEA may display
some neurotoxicity (Sriram et al, 1997). Additional testing to
determine the toxicity profiles of API-59-CJOMe will be required
before this compound can be considered as a possible human
therapeutic. The lack of major effects on the two PTEN-intact cell
lines suggests that normal cells may have some innate resistance to
the compound. However, this will have to be verified in animal
models, as cell culture has only limited capacity to predict in vivo
toxicity.
Our data demonstrate that API-59CJ-OMe can inhibit AKT
kinase activity in cell culture. API-59CJ-OMe does not inhibit ERK
kinase, nor did it affect phosphorylation of ERK1/2, JNK1/2, PKC
isoforms, SGK, PDK1, or AKT itself. This suggests that API-59CJ-
OMe may inhibit the AKT pathway at the AKT level, but not at
upstream kinases that phosphorylate AKT at Serine 473 or
Threonine 308, in endometrial cancer cells. API-59CJ-OMe induces
apoptosis in endometrial cancer cell lines expressing high levels of
AKT activity, but has little effect in endometrial cancer cells
lacking AKT activity. Further, both Ishikawa and RL95-2 cells
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Figure 4 API-59CJ-OMe induces apoptosis of endometrial cancer cells expressing activated AKT. (A) Two examples of flow cytometry histograms in
Ishikawa and KLE cells; API-59CJ-OMe induced marked apoptosis in Ishikawa and RL95-2 cells, but not in Hec1A or KLE cells. (B) Fold increase of apoptosis
was calculated as percentage apoptosis in treated cells over percentage apoptosis in untreated cells. Results shown in (B) are the average and standard
deviation of Log PI from three independent experiments.
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induce p53 targets, mdm2 (data not shown). This suggests that
API-59CJ-OMe does not induce apoptosis through the p53-
dependent pathway. AKT is frequently activated in endometrial
carcinoma due to PTEN mutation, API-59CJ-OMe has potential
clinical applications in endometrial cancer. We plan to further
explore inhibition of AKT pathway using this small molecule
inhibitor in a nude mouse xenograft model.
In addition to endometrial cancer, PTEN is frequently mutated
in brain and prostate cancer (Cairns et al, 1997; Li and Sun, 1998).
AKT activity is also elevated in many ovarian and breast cancers.
In these tumours, AKT activation is mainly due to amplification of
the AKT oncogene or activation by upstream regulators (Cheng
et al, 1992; Bellacosa et al, 1995; Tashiro et al, 1997). It will be of
interest to determine whether API-59CJ-OMe can inhibit other
cancer types with high AKT kinase activity. Our lab has already
shown that API-59CJ-OMe inhibits AKT kinase activity and
induces apoptosis in ovarian cancer cells with high AKT activity
(Tang and Lin, manuscript submitted). These studies represent the
first steps towards developing a small molecule therapy that targets
the AKT oncogenic pathway. This approach may prove useful not
only against endometrial cancer but against prostate cancer, brain
cancer, and other tumours where disruption of PTEN and AKT is
common.
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